Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder of unknown etiology
usually affecting young adults; spiking fever, arthritis and evanescent rash are commonly …

Adult-onset Still's disease (AoSD) is a rare but clinically well-known, polygenic, systemic
autoinflammatory disease. Owing to its sporadic appearance in all adult age groups with …

Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

First described in 1971, adult-onset Still's disease (AOSD) is a rare multisystemic disorder
considered as a complex (multigenic) autoinflammatory syndrome. A genetic background …

IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …

Macrophage activation syndrome (MAS) is a severe, frequently fatal complication of
systemic juvenile idiopathic arthritis (sJIA) with features of hemophagocytosis leading to …

We conducted a retrospective observational study to describe a cohort and identify the
prognostic factors in adult-onset Still disease (AOSD). Patients enrolled in this retrospective …

The molecular mechanisms of acute lung injury resulting in inflammation and fibrosis are not
well established. Here we investigate the roles of the IL-1 receptor 1 (IL-1R1) and the …

Adult-onset Still's disease (AOSD), a systemic inflammatory disorder, is often considered a
part of the spectrum of the better-known systemic-onset juvenile idiopathic arthritis, with later …

Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by
Novartis. Its mode of action is based on the neutralization of IL-1β signaling, resulting in …